SEC Filing Summary: Klotho Neurosciences, Inc. (KLTO)
Business Context and Reporting Period
This Form 8-K Current Report was filed on December 10, 2024, covering events occurring on December 4, 2024. The registrant is Klotho Neurosciences, Inc., a Delaware corporation and emerging growth company. The filing discloses the entry into a material definitive agreement involving debt financing and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
The filing details a specific financing transaction rather than periodic financial performance metrics such as revenue or operating cash flow. Key transaction figures include:
- Debt Instrument: Convertible Promissory Note with a principal amount of $1,200,000.
- Investor: Austria Capital LLC.
- Interest Rate: 0% (Non-interest bearing).
- Discount: 20% Original Issuance Discount (OID).
- Maturity Date: December 4, 2025.
- Equity Issuance: 2,000,000 shares of common stock issued as an inducement to purchase the Note.
- Conversion Terms: Convertible at $0.25 per share, subject to a 4.99% beneficial ownership limitation.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The material change reported is the creation of a new direct financial obligation of $1,200,000 and the dilution of existing shareholders through the issuance of 2,000,000 new shares of common stock.
Outlook, Risks, and Contingencies
Management Commentary: The transaction was executed as a private placement under Section 4(a)(2) of the Securities Act of 1933. The Note is an unsecured obligation ranking equally with existing unsecured indebtedness.
Risks and Contingencies:
- Events of Default: The Note includes specified events of default, including bankruptcy, insolvency, and reorganization, which would allow the investor to demand immediate repayment of all outstanding principal.
- Covenants: The Note does not contain affirmative or restrictive covenants.
- Conversion Restrictions: Conversion is prohibited if the investor would own more than 4.99% of the outstanding common stock.
Investor Verification Checklist
- Verify the exact cash proceeds received after accounting for the 20% original issuance discount.
- Confirm the current total share count to assess the dilution impact of the 2,000,000 inducement shares and potential future conversions.
- Review the full text of the Purchase Agreement (Exhibit 4.1) and Note (Exhibit 4.2) for specific default triggers and conversion adjustment mechanisms.
- Assess the company's liquidity position relative to the $1,200,000 principal due on December 4, 2025.